Global Mycoses Treatment Market, By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), Fungi Type (Dermatophytes, Yeasts, Molds, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Mycoses Treatment Market Analysis and Size
The global mycoses treatment market is expected to witness significant growth during the forecast period. Increasing cases of patients suffering from hospital-acquired or several other infections and infectious diseases is meant to boost the market growth during the forecast period. Evolving markets and huge investment in R&D are the factors that are responsible for the growth of this market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global mycoses treatment market in the forecast period 2022-2029. The expected CAGR of global mycoses treatment market is tend to be around 8% in the mentioned forecast period. The market was valued at USD 431.68 million in 2021, and it would grow upto USD 799 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Mycoses is a type of infection caused by a fungus that leads to chronic diseases mainly affecting skin, hair shaft and nails. It has the inclination to spread into tissues, bones and internal organs. The symptoms depend on the degree of tissue involvement. Weakened immune systems cause mycoses, an immunocompromised state that includes patients with HIV/AIDS and patients treated with corticosteroids for a continued period.
Mycoses Treatment Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), Fungi Type (Dermatophytes, Yeasts, Molds, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland.), Pfizer Inc (U.S.), Lupin (India), Vintage Labs (India), Abbvie Inc. (U.S.), Zydus Group (India), Wockhardt (India), Lannett (U.S.)
Global Mycoses Treatment Market Dynamics
- Increase in Fungal Infections
Fungal diseases are a growing public health crisis. However, there is a severe threat of fungal infections to people with weak immune responses such as patients with AIDS. There is an increasing possibility of the development of fungal infections in these patients. According to the statistics published by the Centers for Disease Control and Prevention in 2016, almost 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year round the world. This boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to increase the market growth. The segment is likely to boost up the global market as many products are available in capsule and tablet form and it is a very convenient route of administration.
- Higher Public-Private Partnerships
There are higher partnerships that are developing with each passing decade. The current public-private partnership agreements in the pharmaceutical industry for the huge development of novel medications are projected to offer huge growth opportunities to the market for mycoses drugs. For instance, CARB-X, an international public-private partnership, is projected to provide about USD 350 million in the coming five years to increase the R&D pipeline. Partners involved are Antimicrobial Resistance Centre in England, the U.S. Department of Health and Human Services, and Boston University School of Law.
- Increasing Demand for Retail Pharmacies
The rise in the number of therapeutics related to mycoses being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Lack of skilled professionals
The lack of healthcare personnel who cannot treat the patients with appropriate treatments could curb the growth of the global mycoses treatment market over a forecast period.
- High Cost
The huge expenditure associated with mycoses medications hamper the market growth as the treatment types involving different drugs such as azoles, echinocandins, polyenes, allylamines are rising high.
This global mycoses treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mycoses treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Mycoses Treatment Market
Over the period of 2020 and 2021, the COVID-19 pandemic had a major impact on most of the medical procedures. People were restricted from visiting hospitals for numerous medical treatments and procedures because of COVID-19 pandemic restrictions. The mycoses treatment range also saw a decline in demand, as the focus was mainly on COVID-19. Additionally, there was a shortage of the equipment, drugs, and materials required to complete successful mycoses treatment procedures. However, the global mycoses treatment market is again regaining its growth with the upliftment of everything and also the shift towards different other diseases.
Global Mycoses Treatment Market Scope
The global mycoses treatment market is segmented on the basis of drug class, fungi type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Amphotericin b
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Mycoses Treatment Market Regional Analysis/Insights
The global mycoses treatment market is analysed and market size insights and trends are provided by drug class, fungi type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global mycoses treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing positive growth for global mycoses treatment market throughout the forecasted period due to global leaders in research and development activities and established healthcare infrastructure.
Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Mycoses Treatment Market Share Analysis
The global mycoses treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mycoses treatment market.
Key players operating in the global mycoses treatment market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Lupin (India)
- Vintage Labs (India
- Abbvie Inc. (U.S.)
- Zydus Group (India)
- Wockhardt (India)
- Lannett (U.S.)